Drug Interactions between Daptacel (DTaP) and sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant

MONITOR: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been adequately assessed. Data from a limited number of adult participants (n=217 Nuvaxovid; n=214 placebo) in an exploratory clinical trial sub-study showed that coadministration of dose 1 of the SARS-CoV-2 (COVID-19) NVX-CoV2373 recombinant vaccine (Nuvaxovid) and inactivated influenza vaccine on the same day resulted in a 30% lower binding antibody response to SARS-CoV-2 as assessed by an anti-spike IgG assay, with no change to influenza vaccine immune responses as measured by hemagglutination inhibition (HAI) assay. However, the seroconversion rates of these participants who received both vaccines together were similar to those of participants in the main study who received Nuvaxovid alone. The clinical significance of these findings is unknown. Concomitant administration of Nuvaxovid with other vaccines has not been studied. Extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously compared to when they are administered alone. Studies that specifically compared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these vaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity, while no specific safety concerns were identified. Taken altogether, the data suggest that COVID-19 vaccines may be coadministered with most other vaccines when necessary.

MANAGEMENT: The U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines and other vaccines may now be administered without regard to timing, including simultaneous administration on the same day as well as coadministration within 14 days (previously, COVID-19 vaccines were recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines). When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If multiple vaccines are administered during a single visit, each injection should be administered at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection, but each injection should be separated by 1 inch or more if possible. It is also advisable to administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus toxoid-containing and adjuvanted vaccines) in different limbs whenever possible.

Switch to consumer interaction data

MONITOR: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been adequately assessed. Data from a limited number of adult participants (n=217 Nuvaxovid; n=214 placebo) in an exploratory clinical trial sub-study showed that coadministration of dose 1 of the SARS-CoV-2 (COVID-19) NVX-CoV2373 recombinant vaccine (Nuvaxovid) and inactivated influenza vaccine on the same day resulted in a 30% lower binding antibody response to SARS-CoV-2 as assessed by an anti-spike IgG assay, with no change to influenza vaccine immune responses as measured by hemagglutination inhibition (HAI) assay. However, the seroconversion rates of these participants who received both vaccines together were similar to those of participants in the main study who received Nuvaxovid alone. The clinical significance of these findings is unknown. Concomitant administration of Nuvaxovid with other vaccines has not been studied. Extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously compared to when they are administered alone. Studies that specifically compared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these vaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity, while no specific safety concerns were identified. Taken altogether, the data suggest that COVID-19 vaccines may be coadministered with most other vaccines when necessary.

MANAGEMENT: The U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines and other vaccines may now be administered without regard to timing, including simultaneous administration on the same day as well as coadministration within 14 days (previously, COVID-19 vaccines were recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines). When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If multiple vaccines are administered during a single visit, each injection should be administered at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection, but each injection should be separated by 1 inch or more if possible. It is also advisable to administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus toxoid-containing and adjuvanted vaccines) in different limbs whenever possible.

Switch to consumer interaction data

MONITOR: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been adequately assessed. Data from a limited number of adult participants (n=217 Nuvaxovid; n=214 placebo) in an exploratory clinical trial sub-study showed that coadministration of dose 1 of the SARS-CoV-2 (COVID-19) NVX-CoV2373 recombinant vaccine (Nuvaxovid) and inactivated influenza vaccine on the same day resulted in a 30% lower binding antibody response to SARS-CoV-2 as assessed by an anti-spike IgG assay, with no change to influenza vaccine immune responses as measured by hemagglutination inhibition (HAI) assay. However, the seroconversion rates of these participants who received both vaccines together were similar to those of participants in the main study who received Nuvaxovid alone. The clinical significance of these findings is unknown. Concomitant administration of Nuvaxovid with other vaccines has not been studied. Extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously compared to when they are administered alone. Studies that specifically compared coadministration of COVID-19 vaccines and seasonal influenza vaccines with separate administration of these vaccines found similar levels of immunogenicity and similar or slightly higher reactogenicity, while no specific safety concerns were identified. Taken altogether, the data suggest that COVID-19 vaccines may be coadministered with most other vaccines when necessary.

MANAGEMENT: The U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines and other vaccines may now be administered without regard to timing, including simultaneous administration on the same day as well as coadministration within 14 days (previously, COVID-19 vaccines were recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines). When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If multiple vaccines are administered during a single visit, each injection should be administered at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection, but each injection should be separated by 1 inch or more if possible. It is also advisable to administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus toxoid-containing and adjuvanted vaccines) in different limbs whenever possible.

Switch to consumer interaction data